Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clini...

This Funding Opportunity Announcement (FOA) invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase l trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/therapeutics/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use. Cooperative Agreement

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities/Indian housing authorities
• Native American tribal organizations (other than Federally recognized tribal governments)
• Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
• Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others